A 2026 review paper in the British Journal of Haematology, titled ‘Integrating novel therapeutic strategies in myeloproliferative neoplasms: Driving disease-directed progress‘ provides for further thoughtful reflection about the future for MPN patients.
The paper highlights the increase in therapeutic options for MPNs over the past decade. And argues for a rethink on how clinicians should be approaching MPNs.
The authors argue that “in parallel, there needs to be a paradigm shift in end-point considerations within MPN clinical trial design, with a growing emphasis on longer term disease stability and modification, molecular responses, histo-morphological modification, reductions in complications (e.g. thrombotic complications or disease transformation) and improved survival alongside the conventional goals such as haematological responses and symptom and spleen improvements where relevant.”
“In this review, we appraise the contemporary therapeutic armamentarium across the MPN spectrum and explore how these advances may best facilitate increasing personalised approaches in an evolving and complex treatment”.
The paper concludes that “MPN represent a complex and evolving spectrum of disorders in which traditional disease classifications and end-points are increasingly insufficient to capture the full breadth of disease biology, patient experience and therapeutic impact.”
“Advances in molecular understanding and the expanding range of targeted and combination therapies are reshaping management… with growing emphasis on symptom burden, quality of life and potential disease modification.”
“However, significant challenges remain, including the need for more meaningful and validated surrogate end-points, improved risk stratification, particularly for disease progression, and clearer definitions of treatment response and failure.”
“The integration of novel agents into clinical practice must also balance efficacy, safety and cost-effectiveness within real-world healthcare systems. Ultimately, future progress will depend on more biologically informed treatment strategies, refined clinical trial design and personalised approaches that align therapeutic intensity with individual patient risk and disease trajectory.”
